HeartSciences Inc. (HSCS): Results of Operations and Financial Condition
HeartSciences Inc. (HSCS) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ea029962701ex99-1.htm PRESS RELEASE, DATED JULY 29, 2026 Exhibit 99.1 HeartSciences Files Preliminary Proxy Statement for Business Combination with Fortitude Mining Holdings; Provides Business Update and Reports Fiscal 2026 Financial Results ● Company believes proposed
How this was made
The 30-second read
Why it matters
For HSCS, the actionable items are the M&A process milestone (proxy filed), the proposed capital structure assumptions in the proxy (including issuance of new shares to DCG), and the stated operational progress (MyoVista Insights commercial launch and MyoVista wavECG FDA 510(k) review). These can affect deal probability, timing expectations, and perceived runway.
Market read
This is a concrete corporate-development update for HSCS, with deal-process and regulatory-review milestones that can drive trading around proxy details and perceived closing odds.
What to watch
Reverse-split authorization (1-for-2 to 1-for-5) can be a sentiment overhang, and the FDA 510(k) submission is still under review, so commercialization claims may not translate into near-term revenue acceleration.
Background
HeartSciences filed an SEC preliminary proxy statement for a previously announced business combination with Fortitude Mining Holdings and simultaneously issued a business update and fiscal 2026 financial results.
Ticker impact
HeartSciences filed a preliminary proxy for a business combination with Fortitude and provided fiscal 2026 financial results plus MyoVista FDA 510(k) status.
Moderate two-sided reaction risk around deal mechanics and reverse-split authorization range, with follow-through tied to proxy details and Nasdaq listing path.
A preliminary proxy is a concrete step toward closing and can change perceived probability and timing, but the filing does not itself confirm approval, final terms, or FDA outcome.
Market effects
Signals continued capital-market activity and consolidation risk/opportunity in healthcare IT and AI-ECG, with potential read-across to small-cap medtech software valuations.
Primarily US-focused, with Nasdaq listing compliance considerations potentially affecting small-cap liquidity and trading behavior.
Limited direct global impact, though the Fortitude/Zcash framing could attract crypto-adjacent investor attention to the combined entity.
Counterpoint
The proxy filing may not materially reduce uncertainty until definitive terms, financing structure, and regulatory or listing approvals are clarified; stock could remain range-bound if details are unfavorable.
Key entities
- companyHeartSciences Inc.
Nasdaq-listed healthcare IT company filing a preliminary proxy for a business combination and reporting fiscal 2026 results.
- companyFortitude Mining Holdings, Inc.
US-based Zcash ecosystem operator proposed as the business combination partner.
- companyDigital Currency Group (DCG)
Parent of Fortitude referenced in the proxy as a party receiving newly issued shares in the transaction.
- regulatorU.S. Securities and Exchange Commission (SEC)
Received the preliminary proxy statement filing referenced in the 8-K.
- regulatorU.S. Food and Drug Administration (FDA)
Reviewing HeartSciences’ MyoVista wavECG 510(k) submission.
